- Bright Minds Biosciences (DRUG) adds three additions to its scientific advisory team for future growth
- Added to the team are John M. McCall, Ph.D., Senior Advisor; Mark A. Geyer, Ph.D., Advisor; and Uros Laban, Senior Chemist
- John M. McCall, Ph.D., is Co-Founder, Chairman of the Board and Vice President of Chemistry at ReveraGen BioPharma
- Mark A. Geyer, Ph.D., is a Distinguished Professor of Psychiatry and Neurosciences Emeritus and Uros Laban, Ph.D., is an experienced medicinal chemist
- Bright Minds Bioscience (DRUG) is up 2.34 per cent and is trading at C$8.75 at close
Bright Minds Biosciences (DRUG) adds three additions to its scientific advisory team for future growth.
Added to the team are John M. McCall, Ph.D., Senior Advisor; Mark A. Geyer, Ph.D., Advisor; and Uros Laban, Senior Chemist.
“We are delighted to welcome John, Mark and Uros to the Bright Minds team. Their collective research, drug development and patent expertise will undoubtedly help us to advance our programs through the clinical phase and ultimately to market,” said CEO Ian McDonald.
“As we expand our cadre of renowned scientific advisors, we look forward to their insights and contributions and to taking full advantage of the opportunities ahead,” added McDonald.
John M. McCall, Ph.D., is Co-Founder, Chairman of the Board and Vice President of Chemistry at ReveraGen BioPharma.
His expertise includes medicinal biochemistry, steroidal chemistry, risk minimization and strategic planning.
Dr. McCall began his career as a medicinal chemist with Upjohn and subsequently held Pharmacia and Pfizer positions.
He was Director of CNS Research with Upjohn, Vice President and Global Head of Chemistry for Pharmacia and Pharmacia Upjohn and Vice President Research with Pfizer.
Dr. McCall received a Ph.D. in Organic Chemistry from the University of Wisconsin and did his postdoctoral work at Harvard University.
Mark A. Geyer, Ph.D., is a Distinguished Professor of Psychiatry and Neurosciences Emeritus at the University of California San Diego (UCSD), where he directs the Neuropsychopharmacology Unit of the VISN 22 Veterans Administration Mental Illness Research, Clinical, and Education Center.
Dr. Geyer received a Ph.D. in Psychology from the University of California San Diego.
Uros Laban, Ph.D., is an experienced medicinal chemist with a breadth of pharmaceutical industry experience across drug development, synthetic chemistry, scale-up, and life sciences.
Considered an expert on psychedelics’ future, Dr. Laban has published numerous books and articles and is a frequent speaker at conferences.
He received a Ph.D. in medicinal chemistry and did postdoctoral work at the Federal University of Rio de Janeiro.
Bright Minds is a pre-clinical biosciences company with a portfolio of compounds designed to precisely target neurocircuitry abnormalities that lead to dysfunctional behaviours.
Bright Minds Bioscience (DRUG) is up 2.34 per cent and is trading at C$8.75 at close.
